The European Union, six of its Member States (Belgium, France, Germany, Lithuania, Sweden and Austria) and the European Investment Bank (EIB) are collectively investing €40 million in a facility belonging to the German biotech company BioNTech for the local manufacturing of RNA-messenger vaccines in Rwanda.
The financial agreement was signed, on Monday 18 December in Kigali, by the President of the European Commission, Ursula von der Leyen, and the President of Rwanda, Paul Kagamé, at...